May 30, 2012 — In an overwhelming 96 to 1 vote last week, the US Senate approved a bill that, among other things, will help to prevent shortages of lifesaving drugs. However, some experts believe that the bill does not go far enough, even though they see it as an important first step. The bipartisan Food and Drug Administration Safety and Innovation Act (SB-3187) will require drug manufacturers to notify the US Food and Drug Administration (FDA) as soon as they anticipate interruptions in drug production, and 6 months in advance if a product will be discontinued. The bill also authorizes $6.4 billion in user fees over the next 5 years for manufacturers seeking the approval of branded and generic drugs, medical devices, and biotechnology products. It is expected that the House of Representatives will pass a similar bill soon — the FDA Reform Act (HR-5651). The American Society of Hematology (ASH) notes that the Senate bill exempts biologics from all provisions, and is p...